- Sartorius and LFB BIOMANUFACTURING have expanded their collaboration to provide biopharmaceutical companies with an integrated service covering cell line development through GMP drug substance manufacturing.
- The collaboration combines Sartorius’ cell line development and master cell bank capabilities with LFB BIOMANUFACTURING’s process development, analytical testing, and manufacturing expertise.
Sartorius and LFB BIOMANUFACTURING have expanded their collaboration to offer biopharmaceutical companies an integrated service spanning cell line development (CLD) to the first batch of GMP drug substance. The companies said the collaboration is intended to simplify and accelerate the path to the clinic for biologics developers.
The expanded relationship builds on a collaboration launched in March 2024. Under the arrangement, Sartorius will contribute expertise in cell line development and master cell bank manufacturing, while LFB BIOMANUFACTURING will provide upstream and downstream process development, analytical development and testing, and GMP drug substance manufacturing capabilities.
According to the companies, the collaboration will provide access to their respective platforms and technologies through a single development pathway. The integrated offering is designed to support clients from early-stage cell line development through manufacturing activities required for clinical programs.
“Our clients are at the center of this collaboration. By collaborating with LFB BIOMANUFACTURING, we combine our cutting-edge CLD technology, including our recently launched genetically engineered host cell line, with expertise from LFB BIOMANUFACTURING in manufacturing, to help our clients achieve success as they take their therapeutics seamlessly to the clinic.”
Stefan Northoff, Head of Cell Line, Media, and Testing Solutions at Sartorius
LFB BIOMANUFACTURING, a CDMO focused on therapeutic proteins, has experience developing monoclonal antibodies, Fc-fusions, bispecifics, and other biologics. Sartorius stated that it has completed more than 330 cell line development projects, with more than 85 programs advancing into clinical development and more than 10 reaching market approval. The companies said the expanded collaboration reflects their commitment to supporting biologics development through integrated services.
